Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073658 · ClinicalTrials.gov registry record · Phase 2
Treating Behavioral Disturbances in Individuals With Dementia
A Phase 2 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 2
- Development phase
- 137
- Enrollment target
NCT00073658: Completed Phase 2 study, sponsored by University of Pittsburgh.
NCT00073658 is a Phase 2 study that has completed, run by University of Pittsburgh. The registered enrollment target is 137 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00073658, a Phase 2 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 137 participants
- Enrollment target
Study Summary
This study will compare the safety and effectiveness two medications, citalopram (Celexa®) and risperidone (Risperdal®).
Interventions
- DRUG Risperidone
- DRUG Citalopram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2000-01 |
| Est. Completion | 2005-06 |
| Phase | Phase 2 |
What the finished NCT00073658 record still lists
NCT00073658 is an interventional study that assigns participants to a tested intervention. The registered 137 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Risperidone is the first listed.
NCT00073658 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00073658 about?
NCT00073658 is a clinical study titled "Treating Behavioral Disturbances in Individuals With Dementia". This study will compare the safety and effectiveness two medications, citalopram (Celexa®) and risperidone (Risperdal®).
What is the current status of trial NCT00073658?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 137 participants. The study started on 2000-01. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00073658?
The interventions under investigation include: Risperidone (DRUG), Citalopram (DRUG).
Who is sponsoring clinical trial NCT00073658?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00073658's enrollment target sits among peer trials
137 527th of 2000 higher than 1,474 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05091424 · 137 participants · Phase 1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- NCT05655182 · 137 participants · Phase 1
A Study of BLB-201 RSV Vaccine in Infants and Children
- NCT06571669 · 137 participants · NA
BOOM-IBD2 Pivotal Clinical Trial
- NCT06644768 · 137 participants · Phase 1
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia